Novartis AG ADR (NVS)vsZevra Therapeutics Inc. (ZVRA)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
ZVRA
Zevra Therapeutics Inc.
$10.17
+5.17%
HEALTHCARE · Cap: $585.24M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 53040% more annual revenue ($56.58B vs $106.47M). ZVRA leads profitability with a 78.2% profit margin vs 23.9%. NVS appears more attractively valued with a PEG of 2.48. ZVRA earns a higher WallStSmart Score of 62/100 (C+).
NVS
Buy51
out of 100
Grade: C-
ZVRA
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Margin of Safety
+62.7%
Fair Value
$22.71
Current Price
$10.17
$12.54 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 86 in profit
Keeps 78 of every $100 in revenue as profit
Revenue surging 183.4% year-over-year
Strong operational efficiency at 27.3%
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
Smaller company, higher risk/reward
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : ZVRA
The strongest argument for ZVRA centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 78.2% and operating margin at 27.3%. Revenue growth of 183.4% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : ZVRA
The primary concerns for ZVRA are EPS Growth, Market Cap, PEG Ratio.
Key Dynamics to Monitor
NVS profiles as a declining stock while ZVRA is a growth play — different risk/reward profiles.
ZVRA carries more volatility with a beta of 0.89 — expect wider price swings.
ZVRA is growing revenue faster at 183.4% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
ZVRA scores higher overall (62/100 vs 51/100), backed by strong 78.2% margins and 183.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Zevra Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company is headquartered in Celebration, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?